Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
8.61
-1.09 (-11.24%)
May 6, 2025, 3:18 PM EDT - Market open
Stoke Therapeutics Employees
Stoke Therapeutics had 128 employees as of December 31, 2024. The number of employees increased by 18 or 16.36% compared to the previous year.
Employees
128
Change (1Y)
18
Growth (1Y)
16.36%
Revenue / Employee
$285,586
Profits / Employee
-$695,164
Market Cap
470.08M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
STOK News
- 4 weeks ago - Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire
- 7 weeks ago - Stoke Therapeutics Stock Slips as CEO Steps Down - Investopedia
- 7 weeks ago - Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Business Wire
- 7 weeks ago - Stoke Therapeutics Announces CEO Transition - Business Wire
- 2 months ago - Stoke Therapeutics to Present at Upcoming Investor Conferences in March - Business Wire
- 2 months ago - Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - Market Watch
- 2 months ago - Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - Business Wire
- 2 months ago - Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha